Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future Directions
- 3.4k Downloads
Insulin receptors in the brain are found in high densities in the hippocampus, a region that is fundamentally involved in the acquisition, consolidation, and recollection of new information. Using the intranasal method, which effectively bypasses the blood–brain barrier to deliver and target insulin directly from the nose to the brain, a series of experiments involving healthy humans has shown that increased central nervous system (CNS) insulin action enhances learning and memory processes associated with the hippocampus. Since Alzheimer's disease (AD) is linked to CNS insulin resistance, decreased expression of insulin and insulin receptor genes and attenuated permeation of blood-borne insulin across the blood–brain barrier, impaired brain insulin signaling could partially account for the cognitive deficits associated with this disease. Considering that insulin mitigates hippocampal synapse vulnerability to amyloid beta and inhibits the phosphorylation of tau, pharmacological strategies bolstering brain insulin signaling, such as intranasal insulin, could have significant therapeutic potential to deter AD pathogenesis.
KeywordsInsulin Memory Alzheimer
Insulin's Scientific Journey from the Periphery to the Brain: a Short Historical Overview
In 1916, the Romanian scientist Nicolae Paulescu showed for the first time that insulin, when injected into diabetic dogs, had a normalizing effect on blood sugar levels . Further research revealed that the ability of certain tissues, such as the skeletal muscle, to utilize glucose essentially depends on the insulin signal , while that of the brain was considered insulin-independent . As a consequence, the general scientific interest in the role insulin might play for brain functions abated. This interest was only revived when insulin receptors (IRs) were ubiquitously detected in both rodent and human brains [4, 5, 6]. The fact that IRs are widely expressed in the brain, combined with evidence that insulin crosses the blood–brain barrier (BBB) by a saturable, receptor-mediated transport mechanism , challenged prevailing scientific concepts that the brain would not be sensitive to insulin, and thus reawakened the scientific interest related to the influence of this hormone on brain functions.
IRs are found in particularly high densities in the hippocampus . This central site is fundamentally involved in the acquisition, consolidation, and recollection of information . In the next section, we will summarize current evidence suggesting that brain insulin signaling influences learning and memory under physiological-like conditions. It is important to keep in mind that insulin also affects neural circuits involved in the regulation of food intake and energy expenditure (e.g., [9, 10, 11]). In order to gain a comprehensive overview regarding the impact of brain insulin pathways on whole-body energy homeostasis, the interested reader is referred to [12, 13, 14].
Effects of Insulin on Memory Processing: from the Needle to the Nose
Hippocampal damage causes severe impairments in the ability of rodents to learn and remember a location in space , highlighting that the hippocampus is an essential support for place memory. Using the intracerebroventricular route, several studies have consistently proven that insulin benefits spatial memory formation by acting at hippocampal sites [16, 17]. For instance, rats receiving an intracerebroventricular injection of insulin after they had been shocked when entering a darkened compartment show an increased latency to enter the same place in a recall session 24 h later . This suggests that insulin enhances memory for the negative consequences associated with spatial orientation.
In humans, it has been shown that postprandial-like increases in plasma insulin levels are followed by increases in cerebrospinal fluid levels of this hormone, indicating that plasma insulin accesses the brain, and therefore potentially affects memory function in humans . Consistent with this assumption, euglycemic hyperinsulinemic clamps have shown that higher, compared to lower doses of intravenous insulin improved verbal memory performance in healthy young men . There are, however, some caveats with this method which limit conclusive interpretation of the data. The continuous glucose infusion during the hyperinsulinemic clamp procedure to ensure euglycemia may exert a biasing impact on cognitive functioning. Moreover, systemic insulin infusions acutely increase serum cortisol levels in healthy men , a hormone which is known to influence core mechanisms of memory processing .
Intranasal Insulin: a Memory Enhancer in Humans?
Insulin Resistance, Cognitive Function, and Alzheimer's Disease: Is There a Link?
Insulin resistance, a key metabolic disturbance of type 2 diabetes, is characterized by reduced responsiveness of target tissues to the insulin signal. Results from population-based studies suggest that insulin resistance is tightly linked to cognitive impairment and smaller brain size [36, 37]. These epidemiological data have been supplemented by recent results showing that men with enhanced peripheral insulin resistance have reduced spontaneous cortical activity, as assessed by magnetoencephalography during euglycaemic insulin infusion . In this study, intravenous infusions of insulin in insulin-resistant subjects induced no changes in beta band activity (commonly associated with increased cortical processing activity; ) and even a decrease of theta band activity (well known to be related to increased memory performance; ) as assessed by magnetoencephalography. In contrast, insulin-sensitive controls showed increased activity in both beta and theta bands in response to intravenous insulin . Further, as revealed by fludeoxyglucose F 18 positron emission tomography (PET), greater insulin resistance has also been linked to reduced cerebral glucose metabolic rates in frontal, parietotemporal, and cingulate regions in elderly, a pattern associated with Alzheimer's disease . These findings therefore provide important evidence supporting the hypothesis that brain insulin signaling is of biological significance for memory functions in humans. This might not be surprising as there is some evidence, albeit limited, that insulin facilitates regional glucose uptake and utilization in the brain .
Remarkably, disturbances in brain insulin signaling have been previously linked to Alzheimer's diseases (AD) . While one study of Japanese patients with AD reported increased fasting levels of cerebrospinal fluid (CSF) insulin , other studies have shown that patients suffering from AD show reduced brain IR activity along with lower CSF insulin levels and peripheral hyperinsulinemia [45, 46] and attenuated insulin and insulin-like growth factor receptor expression . This suggests that disrupted brain insulin signaling may contribute to the loss of memory functions associated with this disease. Since insulin can mitigate the synaptic loss of hippocampal neurons induced by amyloid beta  and regulate glycogen synthase kinase-3 beta, thereby inhibiting the phosphorylation of tau protein that forms neurofibrillary tangles which are a further pathological feature of AD , impaired CNS signaling of the hormone may also promote brain atrophy associated with AD . Against this background, strategies that increase brain insulin concentrations may be expected to counteract AD-related memory deficits and may have therapeutic potential to deter AD pathogenesis. Supporting this assumption, enhancing brain insulin levels in AD patients by intravenous insulin administration has been shown to acutely improve performance on a hippocampus-dependent memory task . However, owing to the notion that high systemic doses would be needed to achieve functionally effective insulin concentrations in the brain, this mode of administration is not viable in the clinical setting. In contrast, intranasal insulin is a promising approach enabling the selective elevation of CNS insulin levels while circumventing risks associated with peripheral administration. As detailed in the next section, convincing evidence has been presented that supports a beneficial effect of intranasal insulin on hippocampus-dependent memory functions in patients with early AD or its prodrome, amnestic mild cognitive impairment (MCI).
Enhancing Brain Insulin Signaling Improves Memory Functions in AD Patients
In a study published in 2006, Reger and coworkers evaluated acute effects of a single intranasal administration of insulin (20 and 40 IU, respectively) on the ability of cognitively impaired patients (i.e., AD and MCI) to recall parts of a story . In detail, subjects heard a brief narrative containing 44 parts of information from a story and were asked to recall as much as possible both immediately and after a 10-min delay. Total verbatim recall was scored. After intranasal administration of either dose of insulin, story recall was particularly improved in those patients who were Epsilon 4 (ε4) negative, with highest performance after 20 IU. The ε4 allele belongs to the apolipoprotein E gene and represents a strong genetic risk factor for late-onset AD . These beneficial effects of intranasal insulin on verbal memory performance were confirmed in separate experiments in that insulin-treated patients retained more verbal information compared with the placebo-assigned group (see also Fig. 2b; [54, 55]). In a very recently published clinical trial including 104 adults with amnestic MCI or mild to moderate AD, 4 months of intranasal insulin administration (20 IU insulin/day) preserved not only general cognition but also improved the metabolic integrity of the brain, as indicated by a fludeoxyglucose F 18 PET . These results suggest that targeting the brain insulin pathway by means of intranasal administration of the hormone is a promising therapeutic strategy to improve memory and potentially deter the process of this devastating disease. Of note, in two of these studies, benefits in episodic memory were found only in those who received a daily dose of 20 IU insulin, while those who received 40 IU did not show an improved recall of episodic memory [54, 56]. These data suggest that intranasal insulin may dose-dependently improve the recall of episodic memories in AD patients. However, it might be also that a larger sample size or a larger set of cognitive tests may also show beneficial effects of 40 IU insulin on episodic memory. Thus, more research to address these issues is needed.
At this point, it is important to emphasize that AD and MCI patients carrying at least one copy of the ε4 allele did not benefit from treatment [52, 54]. One possible explanation for these discrepant results could be that dose–response curves differ by apolipoprotein E genotype. This view is supported by previous findings showing that AD patients without ε4 showed both lower insulin-mediated glucose disposal rates and significant memory facilitation in the hyperinsulinemic condition than did AD patients carrying at least one copy of the ε4 allele , suggesting that defective insulin action may be of particular pathophysiologic significance for patients without an epsilon 4 allele. Thus, it is possible that even the lowest intranasal insulin dose was still too high to induce memory benefits in ε4+ subjects. Alternatively, treatment response differences between APOE groups may reflect differences in the amount of insulin transported to the CNS following intranasal administration. Future research is required to explore these possibilities.
Nevertheless, these findings have piloted an approach that may improve memory function in patients with AD and support further investigation of the benefits of intranasal insulin for patients with Alzheimer's disease. An alternative strategy, which may overcome central insulin resistance in AD that warrants further exploration, involves improving the brain's response to the insulin signal. As mentioned earlier, patients suffering from AD show not only lower CSF insulin levels  but also a reduced IR activity , which could represent a promising target for therapeutic intervention. Insulin sensitizers like the peroxisome proliferator activate receptor gamma agonist rosiglitazone, for example, which might exert its enhancing effects on insulin sensitivity not only in the periphery but also in the CNS. Accordingly, an improved memory function in patients with AD was observed under treatment with rosiglitazone . However, these findings have not been confirmed in a subsequent clinical trial , highlighting the need to find alternative strategies to counteract the reduced brain IR activity in AD patients.
Clinical Safety of Intranasal Insulin Administration
Peripheral insulin elevations have been previously linked to synchronous increases in circulating and CSF concentrations of amyloid beta , elevated blood pressure , and enhanced hypothalamo–pituitary–adrenal  secretory activity. In contrast, subchronic elevations of CNS insulin concentrations by intranasal administration of the hormone have been associated with reduced circulating concentrations of amyloid beta , no changes in blood pressure , and dampened hypothalamo–pituitary–adrenal (HPA) secretory activity , indicating that shorter periods of intranasal insulin apparently do not produce harmful side effects in humans. However, as there is evidence linking reduced insulin signaling in the rodent brain to longevity , larger studies of longer duration are definitely needed to allow final conclusions regarding the clinical safety of insulin treatment in AD.
Approximately six decades after insulin was discovered by Nicolae Paulesco , insulin receptors were ubiquitously found in the CNS  and thus challenged prevailing concepts that the brain is an insulin insensitive organ. In aggregate, the studies briefly summarized above clearly support the idea that brain insulin signaling contributes to hippocampus-dependent learning and memory processes in humans. Further, these studies suggest that enhancing insulin signaling in the brain by means of intranasal administration may be a useful therapeutic option to overcome the CNS insulin resistance found in AD. Employing the combination of insulin sensitizers with intranasal insulin might be another fruitful research direction in order to treat CNS insulin resistance found in AD.
However, some caution is needed when interpreting the effects of intranasal insulin on memory in AD patients. Although promising, the observed effects were small in size in absolute terms and the treatment period was relatively short compared to the duration of AD, and therefore needs confirmation in larger studies of longer duration, in order to fully evaluate the therapeutic potential of intranasal insulin in the treatment of AD. Further, it cannot be ruled out that CNS insulin resistance, under yet unknown pathological conditions, might represent a homeostatic mechanism to counteract chronically elevated CSF concentrations of insulin.
Work from the authors' laboratories was supported by the Tore Nilsons Foundation, Ingrid Thurings Foundation, Brain Foundation, Åke Wiberg Foundation, Novo Nordisk, and the Swedish Research Council.
The authors are unaware of any affiliation, funding, or financial holdings that might be perceived as affecting the objectivity of this review.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
- 1.Paulesco NC (1921) Recherche sur le rôle du pancréas dans l'assimilation nutritive. Archives Internationales de Physiologie 17:85–103Google Scholar
- 23.Frey WH II (1997) Method of administering neurologic agents to the brain. US Patent 5,624,898 filed 1989 and issued April 29, 1997Google Scholar
- 24.Frey WH II (1991) Neurologic agents for nasal administration to the brain. PCT International Patent WO91/07947 filed 1990 and issued June 13, 1991Google Scholar
- 25.Frey WH II (2001) Method for administering insulin to the brain. US Patent 6,313,093 B1 filed 1999 and issued November 6, 2001Google Scholar
- 36.Tan ZS, Beiser AS, Fox CS, Au R, Himali JJ, Debette S, Decarli C, Vasan RS, Wolf PA, Seshadri S (2011) Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study. Diabetes Care 34(8):1766–1770PubMedCrossRefGoogle Scholar
- 38.Tschritter O, Preissl H, Hennige AM, Stumvoll M, Porubska K, Frost R, Marx H, Klösel B, Lutzenberger W, Birbaumer N, Häring HU, Fritsche A (2006) The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A 103(32):12103–12108PubMedCrossRefGoogle Scholar
- 48.De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106(6):1971–1976PubMedCrossRefGoogle Scholar
- 52.Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27(3):451–458PubMedCrossRefGoogle Scholar
- 54.Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, Craft S (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13(3):323–331PubMedGoogle Scholar
- 56.Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2011) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. doi: 10.1001/archneurol.2011.233
- 57.Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, Peskind E, Lofgreen C, Grimwood K (1999) Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70(2):146–152PubMedCrossRefGoogle Scholar
- 58.Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13(11):950–958PubMedGoogle Scholar
- 59.Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30(2):131–146PubMedCrossRefGoogle Scholar
- 60.Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S (2005) Hyperinsulinemia provokes synchronous increases in central and peripheral inflammation and beta amyloid in normal older adults. Arch Neurol 62:1539–1544PubMedCrossRefGoogle Scholar
Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.